LVADs are primarily used where Congestive Heart Failure (CHF)
has progressed to the desperation stage and an implant is required as a medical emergency to avoid imminent death.
Sunshine Heart's C-pulse™ is designed for earlier intervention to halt and in some cases reverse the progression of CHF thus preventing the progression to a medical emergency.
If C-pulse were a new drug in the investigational stage, based on its feasibility trial data, it would be hailed as one of the greatest potential "Blockbuster" drugs of all time;
The C-pulse system is a potential replacement for ineffective Congestive Heart Failure drug therapy addressing a market in the tens of $billions;
C-pulse system's operation and purpose and its target market are quite different to the LVADs from Thoratec (THOR) and Heartware (HTWR).